In previously untreated patients with severe hemophilia A, nearly all inhibitory antibodies (inhibitors) against factor VIII develop within 75 days of exposure, according to research published in Blood. Researchers followed 1038 previously untreated pediatric patients with severe hemophilia A who received treatment with factor VIII. Median age of the cohort at first exposure was 1.1…
Researchers evaluated whether certain brands of recombinant Factor VIII products were associated with increased risk of developing inhibitors.
Treatment strategies for children with hemophilia who have inhibitors should involve eradicating the inhibitor and managing bleeding.
Only factor VIII trough level and prophylactic treatment showed associations with joint health in univariate analysis.
Patients’ responses to surveys assessing quality of life indicated impairment in both adults and adolescents.
Neonates with hemophilia who were delivered either vaginally or by Cesarean section had similar rates of intracranial bleeding.
Researchers reviewed 33 studies published over a span of 20 years to identify risk factors and symptoms of intracranial hemorrhage in patients with hemophilia.
Once-weekly prophylactic injection of glycopegylated recombinant factor VIII (N8‐GP) for severe hemophilia A appears to be efficacious and safe, according to results from the pathfinder 2 extension phase. The study, published in Haemophilia, included patients aged 12 years or older with severe hemophilia A who had experienced up to 2 bleeds during the pathfinder 2…
Current guidelines do not adequately inform management of patients with inherited bleeding disorders undergoing routine dental procedures.
Simplifying factor VIII reconstitution may increase treatment adherence and satisfaction in patients with hemophilia A.
